Bile Duct Adenocarcinoma Non-Resectable
1 clinical trials · Condition
◉ Watch Bile Duct Adenocarcinoma Non-Resectable
| Record | Firm | Date |
|---|---|---|
| Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma (NCT06383533) | Zhejiang Cancer Hospital | 2023-05-01 |
Track Bile Duct Adenocarcinoma Non-Resectable automatically
Every clearance here is in the API, with alerts when new ones post.